Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4B9KS
|
|||
| Drug Name |
Iscalimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| Company |
Novartis Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04129528) Investigator- and Subject-blinded, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy Trial of CFZ533 in Pediatric and Young Adult Subjects With New Onset Type 1 Diabetes (T1DM). U.S.National Institutes of Health. | |||
| REF 2 | Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.